https://www.asm.org/modules/mod_image_show_gk4/cache/Science Advisor Slidegk-is-651.jpglink
https://www.asm.org/modules/mod_image_show_gk4/cache/Amy Chang Bannergk-is-651.jpglink
https://www.asm.org/modules/mod_image_show_gk4/cache/Governance Hero Bannergk-is-651.jpglink
0 1 2
Progress bar
06-12-2016Science Advisor
06-12-2016Amy Chang
06-12-2016Nominate
Become a member today!
JOIN/RENEW
Submit to an ASM Journal
SUBMIT
Attend ASM Biothreat Meeting
REGISTER

 

Dr. Hazuda's research on the HIV-1 integrase enzyme catalyzed the identification of viral integration inhibitors, the validation of this mechanism in vivo, and the understanding of mechanisms of resistance. These accomplishments resulted in the development and approval of raltegravir (tradename ISENTRESS), the first integrase inhibitor licensed for treatment of HIV-1 infection.

TPL_asm2013_SEARCH

91033